Evidence map›Paper›PMID 27981795›Full record

ArticleMolecular nutrition & food research2017

Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.

Luis D Godoy, Julianna E Lucas, Abigail J Bender, Samantha S Romanick, Bradley S Ferguson

Open access · greenAbstract read
In one paragraph

Article in Molecular nutrition & food research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Nutritional Epigenetics in Cancer.Advances in nutrition (Bethesda, Md.) · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Luis D GodoyDepartment Agriculture, Nutrition, & Veterinary Sciences, University of Nevada, Reno, NV, USA.
Julianna E LucasDepartment of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, USA.
Abigail J BenderDepartment of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, USA.
Samantha S RomanickDepartment of Pharmacology, University of Nevada, Reno, NV, USA.
Bradley S FergusonDepartment Agriculture, Nutrition, & Veterinary Sciences, University of Nevada, Reno, NV, USA.
University of Nevada, Reno · US

Funding

Cell Biology of Signaling across MembranesP20GM103554 · NIGMS · UNIVERSITY OF NEVADA RENO · PI VON BARTHELD, CHRISTOPHER S · 2012 to 2016
$8.0M
NIGMS NIH HHS P20 GM103554
6 · The paper itself

Abstract

scopeNutrigenomics is a rapidly expanding field that elucidates the link between diet-genome interactions. Recent evidence demonstrates that regulation of the epigenome, and in particular inhibition of histone deacetylases (HDACs), impact pathogenetic mechanisms involved in chronic disease. Few studies, to date, have screened libraries of bioactive compounds that act as epigenetic modifiers. This study screened a library of 131 natural compounds to determine bioactive compounds that inhibit Zn-dependent HDAC activity. METHODS AND

resultsUsing class-specific HDAC substrates, we screened 131 natural compounds for HDAC activity in bovine cardiac tissue. From this screen, we identified 18 bioactive compound HDAC inhibitors. Using our class-specific HDAC substrates, we next screened these 18 bioactive compounds against recombinant HDAC proteins. Consistent with inhibition of HDAC activity, these compounds were capable of inhibiting activity of individual HDAC isoforms. Lastly, we report that treatment of H9c2 cardiac myoblasts with bioactive HDAC inhibitors was sufficient to increase lysine acetylation as assessed via immunoblot.

conclusionThis study provided the first step in identifying multiple bioactive compound HDAC inhibitors. Taken together, this report sets the stage for future exploration of these bioactive compounds as epigenetic regulators to potentially ameliorate chronic disease.

Indexed as

EpigenomicsAcetylationAnimalsCattleHistone Deacetylase 1Histone Deacetylase InhibitorsHistone DeacetylasesHistonesHumansProtein IsoformsProtein Processing, Post-TranslationalZincHistone Deacetylase 1Histone Deacetylase InhibitorsHistone DeacetylasesHistonesProtein IsoformsZincAcetylationBioactive compoundsDietary HDAC inhibitorsHDACsHistone deacetylases

Identifiers

PMID27981795
PMCPMC5508980
OpenAlexW2561792783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.